Effects of nanoparticle coatings on the activity of oncolytic adenovirus-magnetic nanoparticle complexes

Biomaterials

Volumn 33, Issue 1, 2012, Pages 256-269

  Tresilwised, Nittaya ^a,b   Pithayanukul, Pimolpan ^a   Holm, Per Sonne ^b   Schillinger, Ulrike ^b   Plank, Christian ^b   Mykhaylyk, Olga ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Magnetic nanoparticles; Multidrug resistant cancer cells; Oncolytic activity; Oncolytic adenovirus; Surface coating

Indexed keywords

CORE-SHELL-TYPE; CRITICAL DETERMINANT; HIGH-SATURATION MAGNETIZATION; INHIBITORY EFFECT; INTRATUMORAL INJECTION; MAGNETIC FIELD INFLUENCE; MAGNETIC NANOPARTICLES; MAGNETIC PARTICLE; MULTIDRUG-RESISTANT CANCER CELLS; NANOPARTICLE COATINGS; NEUTRALIZING ANTIBODIES; ONCOLYTIC ADENOVIRUS; PHYSICOCHEMICAL PROPERTY; POLYETHYLENIMINES; SERUM CONCENTRATION; SILICA COATINGS; SURFACE COATING; SURFACE COATINGS; TUMOR GROWTH;

ANTIBODIES; BODY FLUIDS; COATINGS; IRON OXIDES; MAGNETIC BUBBLES; MAGNETIC FIELD EFFECTS; MAGNETIC MOMENTS; MAGNETIC PROPERTIES; NANOPARTICLES; PRODUCTIVITY; SATURATION MAGNETIZATION; SILICA; VIRUSES;

NANOMAGNETICS;

IRON OXIDE; MAGNETIC NANOPARTICLE; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS 520; POLYETHYLENEIMINE; SILICON DIOXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PARTICLE SIZE; PHYSICOCHEMICAL MODEL; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; MAGNETITE NANOPARTICLES; MICE; MICE, NUDE; NANOPARTICLES; ONCOLYTIC VIRUSES;

ADENOVIRIDAE;

EID: 82855172101     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.028     Document Type: Article

References (51)

1. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets 2000, 1(1):85-99.
2. Davis J.J., Fang B. Oncolytic virotherapy for cancer treatment: challenges and solutions. J Gene Med 2005, 7(11):1380-1389.
3. Heise C., Kirn D.H. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000, 105(7):847-851.
4. Kowalski J.B., Tallentire A. Substantiation of 25 kGy as a sterilization dose: a rational approach to establishing verification dose. Radiat Phys Chem 1999, 54(1):55-64.
5. Douglas J.T., Kim M., Sumerel L.A., Carey D.E., Curiel D.T. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001, 61(3):813-817.
6. Rein D.T., Breidenbach M., Curiel D.T. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2006, 2(1):137-143.
7. Mizuguchi H., Hayakawa T. Targeted adenovirus vectors. Hum Gene Ther 2004, 15(11):1034-1044.
8. Haim H., Steiner I., Panet A. Synchronized infection of cell cultures by magnetically controlled virus. J Virol 2005, 79(1):622-625.
9. Schillinger U., Brill T., Rudolph C., Huth S., Gersting S., Krotz F., et al. Advances in magnetofection - magnetically guided nucleic acid delivery. J Magn Magn Mat 2005, 293(1):501-508.
10. Huth S., Lausier J., Gersting S.W., Rudolph C., Plank C., Welsch U., et al. Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med 2004, 6(8):923-936.
11. Kadota S., Kanayama T., Miyajima N., Takeuchi K., Nagata K. Enhancing of measles virus infection by magnetofection. J Virol Methods 2005, 128(1-2):61-66.
12. Scherer F., Anton M., Schillinger U., Henke J., Bergemann C., Kruger A., et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002, 9(2):102-109.
13. Tresilwised N., Pithayanukul P., Mykhaylyk O., Holm P.S., Holzmuller R., Anton M., et al. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force. Mol Pharmaceutics 2010, 7(4):1069-1089.
14. Gupta A.K., Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26(18):3995-4021.
15. Jain T.K., Reddy M.K., Morales M.A., Leslie-Pelecky D.L., Labhasetwar V. Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharmaceutics 2008, 5(2):316-327.
16. Veiseh O., Gunn J.W., Zhang M.Q. Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging. Adv Drug Deliv Rev 2010, 62(3):284-304.
17. McBain S.C., Yiu H.H.P., El Haj A., Dobson J. Polyethyleneimine functionalized iron oxide nanoparticles as agents for DNA delivery and transfection. J Mater Chem 2007, 17(24):2561-2565.
18. Bhattarai S.R., Kim S.Y., Jang K.Y., Lee K.C., Yi H.K., Lee D.Y., et al. Laboratory formulated magnetic nanoparticles for enhancement of viral gene expression in suspension cell line. J Virol Methods 2008, 147(2):213-218.
19. Mykhaylyk O., Antequera Y.S., Vlaskou D., Plank C. Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc 2007, 2(10):2391-2411.
20. Gonzalez-Fernandez M.A., Torres T.E., Andres-Verges M., Costo R., de la Presa P., Serna C.J., et al. Magnetic nanoparticles for power absorption: optimizing size, shape and magnetic properties. J Solid State Chem 2009, 182(10):2779-2784.
21. Morishita N., Nakagami H., Morishita R., Takeda S., Mishima F., Terazono B., et al. Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector. Biochem Biophys Res Commun 2005, 334(4):1121-1126.
22. Sanchez-Antequera Y., Mykhaylyk O., Thalhammer S., Plank C. Gene delivery to jurkat T cells using non-viral vectors associated with magnetic nanoparticles. Int J Biomed Nanoscience Nanotechnology 2010, 1(2/3/4):202-229.
23. Schladt T.D., Schneider K., Schild H., Tremel W. Synthesis and bio-functionalization of magnetic nanoparticles for medical diagnosis and treatment. Dalton Trans 2011, 40(24):6315-6343.
24. Sanchez-Antequera Y., Mykhaylyk O., van Til N.P., Cengizeroglu A., de Jong J.H., Huston M.W., et al. Magselectofection: an integrated method of nanomagnetic separation and genetic modification of target cells. Blood 2011, 117(16):E171-E181.
25. Holm P.S., Lage H., Bergmann S., Jurchott K., Glockzin G., Bernshausen A., et al. Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res 2004, 64(1):322-328.
26. Holm P.S., Scanlon K.J., Dietel M. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer 1994, 70(2):239-243.
27. Mittereder N., March K.L., Trapnell B.C. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 1996, 70(11):7498-7509.
28. Mykhaylyk O., Sanchez-Antequera Y., Vlaskou D., Hammerschmid E., Anton M., Zelphati O., et al. Liposomal magnetofection. Methods Mol Biol 2010, 605:487-525.
29. Mykhaylyk O., Vlaskou D., Tresilwised N., Pithayanukul P., Möller W., Plank C. Magnetic nanoparticle formulations for DNA and siRNA delivery. J Magn Magn Mat 2007, 311(1):275-281.
30. Krill C.E., Birringer R. Estimating grain-size distributions in nanocrystalline materials from X-ray diffraction profile analysis. Philos Mag A 1998, 77(3):621-640.
31. Mykhaylyk O., Zelphati O., Rosenecker J., Plank C. siRNA delivery by magnetofection. Curr Opinion Molecular Therapeutics 2008, 10(5):493-505.
32. Mykhaylyk O., Zelphati O., Hammerschmid E., Anton M., Rosenecker J., Plank C. Recent advances in magnetofection and its potential to deliver siRNAs in vitro. Methods Mol Biol 2009, 487:111-146.
33. Mikhaylova M., Kim D.K., Bobrysheva N., Osmolowsky M., Semenov V., Tsakalakos T., et al. Superparamagnetism of magnetite nanoparticles: dependence on surface modification. Langmuir 2004, 20(6):2472-2477.
34. Oliver C.J., Shortridge K.F., Belyavin G. Diffusion-coefficient and molecular-weight of type-5 adenovirus by photon-correlation spectroscopy. Biochim Biophys Acta 1976, 437(2):589-598.
35. Ferreira T.B., Alves P.M., Gonçalves D., Carrondo M.J.T. Effect of MOI and medium composition on adenovirus infection kinetics. Animal cell technology meets genomics 2005, 329-332. Springer, The Netherlands. F. Gòdia, M. Fussenegger (Eds.).
36. Pan X., Guan J., Yoo J.W., Epstein A.J., Lee L.J., Lee R.J. Cationic lipid-coated magnetic nanoparticles associated with transferrin for gene delivery. Int J Pharm 2008, 358(1-2):263-270.
37. Zheng X., Lu J., Deng L., Xiong Y., Chen J. Preparation and characterization of magnetic cationic liposome in gene delivery. Int J Pharm 2009, 366(1-2):211-217.
38. Smith J.G., Cassany A., Gerace L., Ralston R., Nemerow G.R. Neutralizing antibody blocks adenovirus infection by arresting microtubule-dependent cytoplasmic transport. J Virol 2008, 82(13):6492-6500.
39. Wang Y., Hu J.K., Krol A., Li Y.P., Li C.Y., Yuan F. Systemic dissemination of viral vectors during intratumoral injection. Mol Cancer Ther 2003, 2(11):1233-1242.
40. Nicklin S.A., Wu E., Nemerow G.R., Baker A.H. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 2005, 12(3):384-393.
41. Arsianti M., Lim M., Marquis C.P., Amal R. Polyethylenimine based magnetic iron-oxide vector: the effect of vector component assembly on cellular entry mechanism, intracellular localization, and cellular viability. Biomacromolecules 2010, 11(9):2521-2531.
42. Arsianti M., Lim M., Marquis C.P., Amal R. Assembly of polyethylenimine-based magnetic iron oxide vectors: insights into gene delivery. Langmuir 2010, 26(10):7314-7326.
43. Ito A., Takahashi T., Kameyama Y., Kawabe Y., Kamihira M. Magnetic concentration of a retroviral vector using magnetite cationic liposomes. Tissue Eng Part C Methods 2009, 15(1):57-64.
44. Park I.K., Ng C.P., Wang J., Chu B., Yuan C., Zhang S., et al. Determination of nanoparticle vehicle unpackaging by MR imaging of a T2 magnetic relaxation switch. Biomaterials 2008, 29(6):724-732.
45. Itaka K., Harada A., Nakamura K., Kawaguchi H., Kataoka K. Evaluation by fluorescence resonance energy transfer of the stability of nonviral gene delivery vectors under physiological conditions. Biomacromolecules 2002, 3(4):841-845.
46. Chen Z.P., Xu R.Z., Zhang Y., Gu N. Effects of proteins from culture medium on surface property of silanes-functionalized magnetic nanoparticles. Nanoscale Res Lett 2009, 4:204-209.
47. Moghimi S.M., Symonds P., Murray J.C., Hunter A.C., Debska G., Szewczyk A. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. Mol Ther 2005, 11(6):990-995.
48. Namgung R., Singha K., Yu M.K., Jon S., Kim Y.S., Ahn Y., et al. Hybrid superparamagnetic iron oxide nanoparticle-branched polyethylenimine magnetoplexes for gene transfection of vascular endothelial cells. Biomaterials 2010, 31(14):4204-4213.
49. Boussif O., Lezoualch F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in-vivo - polyethylenimine. Proc Natl Acad Sci USA 1995, 92(16):7297-7301.
50. Plank C., Oberhauser B., Mechtler K., Koch C., Wagner E. The influence of endosome-disruptive peptides on gene-transfer using synthetic virus-like gene-transfer systems. J Biol Chem 1994, 269(17):12918-12924.
51. Campbell S.A., Gromeier M. Oncolytic viruses for cancer therapy I. Cell-external factors: virus entry and receptor interaction. Onkologie 2005, 28(3):144-149.